Cargando…

Dysregulated connexin 43 in HER2-positive drug resistant breast cancer cells enhances proliferation and migration

Connexin 43 (Cx43) is a gap junction protein whose function in the development of breast cancer and in breast cancer progression remains unclear. Evidence suggests that Cx43 (GJA1) mRNA and protein expression is altered in breast tumors. However, reports indicate both increased and decreased Cx43 le...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeh, Elizabeth S., Williams, Christina J., Williams, Carly Bess, Bonilla, Ingrid V., Klauber-DeMore, Nancy, Phillips, Stephanie L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752526/
https://www.ncbi.nlm.nih.gov/pubmed/29312613
http://dx.doi.org/10.18632/oncotarget.22678
_version_ 1783290124272926720
author Yeh, Elizabeth S.
Williams, Christina J.
Williams, Carly Bess
Bonilla, Ingrid V.
Klauber-DeMore, Nancy
Phillips, Stephanie L.
author_facet Yeh, Elizabeth S.
Williams, Christina J.
Williams, Carly Bess
Bonilla, Ingrid V.
Klauber-DeMore, Nancy
Phillips, Stephanie L.
author_sort Yeh, Elizabeth S.
collection PubMed
description Connexin 43 (Cx43) is a gap junction protein whose function in the development of breast cancer and in breast cancer progression remains unclear. Evidence suggests that Cx43 (GJA1) mRNA and protein expression is altered in breast tumors. However, reports indicate both increased and decreased Cx43 levels in human breast cancer samples. Studies also suggest that loss of Cx43 regulated gap junction intercellular communication is a common feature of breast malignancies that potentially correlates with histological stage. Further evidence suggests that Cx43 (GJA1) mRNA expression is negatively correlated with HER2 positivity but a relationship between Cx43 and HER2 in breast cancer is not well defined. Therefore, in this study, we sought to evaluate the relationship between Cx43 activity, HER2, and drug resistance. Using HER2+ breast cancer cell lines that are sensitive or resistant to HER2 inhibitor, we evaluated Cx43 gap junction function. We found that Cx43 gap junction activity is completely lost in drug resistant HER2-positive (HER2+) breast cancer cells, whereas Cx43 gap junction activity can be restored by Cx43 overexpression in drug sensitive HER2+ cells. Moreover, the dysregulation of Cx43 resulted in increased tumorigenic and migratory capacity of the HER2+ drug resistant breast cancer cells.
format Online
Article
Text
id pubmed-5752526
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-57525262018-01-08 Dysregulated connexin 43 in HER2-positive drug resistant breast cancer cells enhances proliferation and migration Yeh, Elizabeth S. Williams, Christina J. Williams, Carly Bess Bonilla, Ingrid V. Klauber-DeMore, Nancy Phillips, Stephanie L. Oncotarget Research Paper Connexin 43 (Cx43) is a gap junction protein whose function in the development of breast cancer and in breast cancer progression remains unclear. Evidence suggests that Cx43 (GJA1) mRNA and protein expression is altered in breast tumors. However, reports indicate both increased and decreased Cx43 levels in human breast cancer samples. Studies also suggest that loss of Cx43 regulated gap junction intercellular communication is a common feature of breast malignancies that potentially correlates with histological stage. Further evidence suggests that Cx43 (GJA1) mRNA expression is negatively correlated with HER2 positivity but a relationship between Cx43 and HER2 in breast cancer is not well defined. Therefore, in this study, we sought to evaluate the relationship between Cx43 activity, HER2, and drug resistance. Using HER2+ breast cancer cell lines that are sensitive or resistant to HER2 inhibitor, we evaluated Cx43 gap junction function. We found that Cx43 gap junction activity is completely lost in drug resistant HER2-positive (HER2+) breast cancer cells, whereas Cx43 gap junction activity can be restored by Cx43 overexpression in drug sensitive HER2+ cells. Moreover, the dysregulation of Cx43 resulted in increased tumorigenic and migratory capacity of the HER2+ drug resistant breast cancer cells. Impact Journals LLC 2017-11-25 /pmc/articles/PMC5752526/ /pubmed/29312613 http://dx.doi.org/10.18632/oncotarget.22678 Text en Copyright: © 2017 Yeh et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Yeh, Elizabeth S.
Williams, Christina J.
Williams, Carly Bess
Bonilla, Ingrid V.
Klauber-DeMore, Nancy
Phillips, Stephanie L.
Dysregulated connexin 43 in HER2-positive drug resistant breast cancer cells enhances proliferation and migration
title Dysregulated connexin 43 in HER2-positive drug resistant breast cancer cells enhances proliferation and migration
title_full Dysregulated connexin 43 in HER2-positive drug resistant breast cancer cells enhances proliferation and migration
title_fullStr Dysregulated connexin 43 in HER2-positive drug resistant breast cancer cells enhances proliferation and migration
title_full_unstemmed Dysregulated connexin 43 in HER2-positive drug resistant breast cancer cells enhances proliferation and migration
title_short Dysregulated connexin 43 in HER2-positive drug resistant breast cancer cells enhances proliferation and migration
title_sort dysregulated connexin 43 in her2-positive drug resistant breast cancer cells enhances proliferation and migration
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752526/
https://www.ncbi.nlm.nih.gov/pubmed/29312613
http://dx.doi.org/10.18632/oncotarget.22678
work_keys_str_mv AT yehelizabeths dysregulatedconnexin43inher2positivedrugresistantbreastcancercellsenhancesproliferationandmigration
AT williamschristinaj dysregulatedconnexin43inher2positivedrugresistantbreastcancercellsenhancesproliferationandmigration
AT williamscarlybess dysregulatedconnexin43inher2positivedrugresistantbreastcancercellsenhancesproliferationandmigration
AT bonillaingridv dysregulatedconnexin43inher2positivedrugresistantbreastcancercellsenhancesproliferationandmigration
AT klauberdemorenancy dysregulatedconnexin43inher2positivedrugresistantbreastcancercellsenhancesproliferationandmigration
AT phillipsstephaniel dysregulatedconnexin43inher2positivedrugresistantbreastcancercellsenhancesproliferationandmigration